Latest news with #HispanicPatients
Medscape
9 hours ago
- Health
- Medscape
A Simple Way to Close Racial Gaps in Cancer Trial Enrollment
TOPLINE: In a single-center survey, patients with breast cancer from different racial and ethnic backgrounds were equally likely to discuss and participate in clinical trials when given the opportunity. Among patients who declined to participate, ineligibility and time commitment emerged as key barriers. METHODOLOGY: Clinical trials are crucial for advancing breast cancer care, but enrollment among Black and Hispanic women remains disproportionately low, resulting in study populations that do not reflect the diversity of patients with breast cancer. Some studies suggest that when given the opportunity, Black and Hispanic patients are just as willing to participate in clinical trials as their White counterparts. To better understand discussions, participation as well as patient attitudes surrounding clinical trials, researchers analyzed survey responses from 1150 patients with breast cancer who were enrolled in the Chicago Multiethnic Epidemiologic Breast Cancer Cohort and responded to a survey between July and September 2022. Among them, 4.4% were Asian, 19.5% Black, 3.1% Hispanic, and 73.0% White individuals; mean age at diagnosis was just under 54 years. Compared with White patients, Black patients had increased proportions of triple-negative breast cancer (TNBC; 14.6% vs 25.0%) and grade 3 tumors (36.9% vs 55.5%). Outcomes of interest were discussions of clinical trials, actual participation, and barriers to participation. TAKEAWAY: Among survey respondents, 447 (38.9%) reported discussing trial participation with healthcare practitioners, with no significant differences between different racial/ethnic groups (adjusted odds ratios, 0.75 for Asian, 1.31 for Black, 0.73 for Hispanic patients compared to White patients). Of the 443 patients who were offered trials, 64.3% participated. Patients who were younger, had more advanced disease, or were diagnosed with TNBC or high-grade cancer were more likely to be offered a clinical trial. While there were differences in trial participation rates across racial and ethnic groups, they were not significantly different after adjusting for sociodemographic and clinical factors. Among 158 patients who declined to participate, the primary reasons were ineligibility and lack of interest in trials (23.4% for both) as well as concerns about receiving placebo (10.8%) and the time requirement (10.1%). Patients with an annual household income below $150,000 were also significantly less likely to participate than those with an income of $150,000 or more but this association varied by income bracket, suggesting that financial barriers are more nuanced than annual income alone. IN PRACTICE: The study adds to evidence that patients from racial minority groups are just as willing to enroll in clinical trials when given the chance, according to an invited commentary by Joseph M. Unger, PhD, MS, Fred Hutch Cancer Center, Seattle. The results also 'lend crucial validation' to prior findings showing that structural and clinical barriers — not patient refusal — are the main reasons for trial non-participation, according to Unger. 'Reducing barriers to enrollment of clinical trials is a scientific and ethical imperative for the cancer community,' the study authors said. SOURCE: This study, led by Nan Chen, MD, University of Chicago, Illinois, was published online in JAMA Network Open. LIMITATIONS: The study population may not have fully represented the broader population of patients with breast cancer in the US. The analysis also lacked sufficient statistical power to detect significant differences in clinical trial discussion and participation between Asian or Hispanic patients and White patients given limited sample sizes. Additionally, survey-based data collection may have introduced selection bias as respondents were likely healthier or had positive experiences with clinical trial discussion or participation. DISCLOSURES: This study was supported partly by grants from the Breast Cancer Research Foundation, National Cancer Institute, Susan G. Komen Breast Cancer Foundation, and National Institute on Aging. Two authors reported receiving personal fees or grants from various sources, outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
08-06-2025
- Health
- Yahoo
Ontada Unveils Comprehensive Data on Social Determinants of Health and Outcomes of Early-Onset Colorectal Cancer at ASCO
Findings show Black and Hispanic Patients Have 30% Higher Risk of Advanced-Stage Diagnosis BOSTON, May 30, 2025--(BUSINESS WIRE)--Ontada®, a leader in real-world oncology data and insights, is proud to present its latest research findings in a pivotal oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, titled, "Real-world Social Determinants of Health and Outcomes of Early-onset Colorectal Cancer: An Analysis of a Large Nationally Representative US Community Oncology Network," provides critical data on the impact of social determinants on the outcomes of early-onset colorectal cancer (EO-CRC) patients, and offers one of the largest studies of EO-CRC to date. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Key Data Findings Racial and ethnic disparities: A higher burden of EO-CRC was observed among patients of Black and American Indian/Alaskan Native race and Hispanic/Latino ethnicity. Obesity as a risk factor: There was a 5% higher prevalence of obesity among patients with early-onset CRC versus average onset CRC. More advanced stage at diagnosis for EO-CRC: Patients with EO-CRC have an 11% greater likelihood of diagnosis at Stage III or IV disease as compared to average-onset disease. Poorer survival associated with advancing age: At each cancer stage, patients with EO-CRC had a longer overall survival as compared to patients with average-onset CRC, reflecting existing knowledge about cancer survival decreasing with advancing age. Importance of screening and earlier diagnosis: Among all patients with CRC, including early-onset diagnosis, disease stage at diagnosis was the strongest predictor of overall survival, reflecting the importance of earlier detection and screening programs for all. "Understanding the complex interplay between social factors and cancer incidence and outcomes is crucial for developing effective, patient-centered care strategies, and this research underscores the importance of understanding and then intervening on social determinants of health to improve care for patients with EO-CRC," said Jessica K. Paulus, ScD, senior director, Real-World Research, Ontada. "Ontada's data provides a clear and compelling picture of the impact of social determinants on the outcomes of patients with EO-CRC. By leveraging our unique data emanating from the nationally representative The US Oncology Network and our measures of social determinants at scale, we can drive meaningful changes in clinical practice and policy, ultimately improving patient care and outcomes." Study Methodology This retrospective observational cohort study examined adult CRC patients within The US Oncology Network and non-Network practices, encompassing over 2,700 community-based providers treating more than 1.4 million patients annually. All patients diagnosed with CRC between 2000 and 2024 were included; patients were categorized as EO-CRC if they were <50 years at first diagnosis and average-onset (AO)-CRC otherwise. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Patient characteristics were sourced from iKnowMed, an oncology-specific electronic health record system, and descriptively summarized. Overall Survival (OS) was assessed from diagnosis using Kaplan-Meier methods. Other Research at ASCO 2025 Ontada is showcasing its research capabilities at ASCO with 12 accepted abstracts on topics such as using large language models to extract cancer data, accelerating Phase 2 clinical development with real-world data in HER2-positive metastatic breast cancer, validating real-world event-free survival in early-stage triple negative breast cancer, analyzing outcomes of BRAF-mutated melanoma patients, and providing a descriptive epidemiology of Waldenström Macroglobulinemia. "At Ontada, we are at the forefront of transforming cancer care through the power of real-world data and insights," said Christine Davis, president, Ontada. "Our extensive research at ASCO 2025 underscores our commitment to driving meaningful advancements in oncology. This research will not only highlight the critical role of real-world evidence in improving patient outcomes but also demonstrate our dedication to addressing the complex challenges faced by cancer patients and healthcare providers." Ontada is a part of McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. For a comprehensive list of Ontada abstracts and presentations, visit Ontada's ASCO 2025 Site. Additionally, visit the Ontada Booth (#35093) at the McCormick Place Convention Center from May 30 – June 3 to explore the data presented at ASCO 2025 and experience Ontada's solutions firsthand. About Ontada® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines. View source version on Contacts Media Contact OntadaClaire Crye, Communications281.825.9927 GCI Health on behalf of OntadaChristine Murphy, Media Relations201.230.9636 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
07-05-2025
- Health
- Medscape
Uterine Cancer Survival Varies Widely by Race Across US
A study of 162,500 patients with uterine cancer found that survival rates varied significantly by race and geographic location, with Black patients experiencing the worst survival outcomes in areas with high and low overall diversity. METHODOLOGY: Despite known racial and ethnic disparities in uterine cancer survival in the United States, data on the association between geographic region and these disparities remain limited. A retrospective cohort study analyzed outcomes from 162,500 patients with uterine cancer (median age, 61 years at diagnosis) between 2000 and 2019 from 17 Surveillance, Epidemiology, and End Results (SEER) registries. Researchers categorized patients by race and ethnicity: 7.5% were Asian individuals, 8.6% were Black individuals, 12.8% were Hispanic individuals, and 71.1% were White individuals. Geographic locations were ranked from 0% to 100% by the US Census Bureau's Diversity Index, with higher values indicating greater diversity. Values varied from 76.0% for Hawaii to 30.8% for Iowa. The primary outcome was uterine cancer–specific survival. The median follow-up durations were 84 months for Asian patients, 59 months for Black patients, 73 months for Hispanic patients, and 93 months for White patients. TAKEAWAY: Compared with White patients, Asian patients had better cancer-specific survival (hazard ratio [HR], 0.91), whereas Black patients had worse cancer-specific survival (HR, 1.34), and cancer-specific survival for Hispanic patients was similar (HR, 1.01; 95% CI, 0.97-1.06 ). Black patients experienced worse survival than White patients in both high-diversity areas (HR, 1.34 in California and New Jersey; HR, 1.39 in Georgia) and low-diversity locations (HR, 1.34 in Louisiana; HR, 1.42 in Connecticut; HR, 1.71 in Iowa). Compared with White patients, Hispanic patients showed worse survival in Hawaii (HR, 2.09) and Georgia (HR, 1.44), whereas Asian patients demonstrated better survival in California (HR, 0.91). Black patients with low-grade endometrioid, nonendometrioid, and early-stage disease had worse survival in Louisiana than White patients (HRs 2.08, 1.29, and 1.77, respectively), and those with high-grade endometrioid disease in Seattle and nonendometrioid disease in Iowa also had worse outcomes (HRs, 2.23 and 2.01, respectively). IN PRACTICE: 'In this cohort study of patients with uterine cancer, racially and ethnically disparate uterine cancer–specific survival was observed in specific geographic locations,' the authors wrote. 'While etiologic studies that assess the causes of geographically defined racially and ethnically disparate uterine cancer survival are needed, our findings suggest that locations with the most pronounced racial and ethnic disparities should be prioritized.' SOURCE: The study, led by Caitlin E. Meade, Division of Epidemiology, College of Public Health, Ohio State University in Columbus, Ohio, was published online in JAMA Network Open . LIMITATIONS: The analysis focused was limited to 11 locations with SEER registries. The researchers noted that the low power in areas with lower diversity indices might have affected the detection of racial and ethnic disparities. The study also lacked other measures of structural inequities and systemic discrimination that could contextualize the findings. DISCLOSURES: The study received grants from the National Cancer Institute. Several authors reported receiving personal fees or grants from various sources.
